Bellast Ultra Plus Dermal Filler
High-density cross-linked HA filler with 24mg/ml concentration & 99.1% monophasic gel integrity
Advanced Cross-Linking Technology
Manufactured under ISO 13485 standards using patented V-Matrix™ technology (KR Patent 1020230078915), Bellast Ultra Plus achieves G’ value of 420Pa with BDDE residual <1.5ppm. Contains 0.3% lidocaine HCl and endotoxin levels <0.5 EU/ml (validated by chromogenic assay). Particle size distribution maintained at 300-500μm for optimal tissue integration.
Clinical Advantages
Enhanced Viscosity
G’ 420Pa provides superior lifting capacity for deep wrinkle correction
Safety Certified
BDDE residual <1.5ppm (HPLC verified) with 99.9% non-animal origin
Longevity
12-month persistence confirmed in 24-month multicenter study (n=214)
Product Specifications
- Active Ingredients: HA 24mg/ml, Lidocaine 0.3%
- BDDE Residual: <1.5ppm
- Packaging: 1×1.0ml sterile syringe
- Viscosity: G’ 420Pa @2Hz
- Certification: ISO 13485:2016, KFDA Approved
Clinical Protocol
- Needle: 27G×13mm cannula
- Depth: Deep dermis (2.5-4.0mm)
- Max Volume: 1.2ml per session
- Technique: Bolus injection or linear retrograde
Indications
Nasolabial Folds
Inject 0.4-0.6ml per fold using cannula technique. Maintain supraperiosteal placement for structural support.
Cheek Augmentation
Limit to 1.0ml per cheek. Use fanning technique in deep fat compartments.
Marionette Lines
Administer 0.5-0.8ml per side using blunt cannula at subdermal level.
Medical Notice
Important: Individual results may vary depending on injection technique and tissue characteristics. Must be administered by certified dermatologists or plastic surgeons. Contraindicated in patients with autoimmune disorders or hypersensitivity to lidocaine.
Post-procedure observation required for 45 minutes. Not for use in periorbital area. Store at 15-30°C. Discard unused product immediately. Manufacturer not liable for off-label use.
